SURGICAL AND COMBINED TREATMENT OF LOCALLY ADVANCED GASTRIC CANCER
Keywords:
stomach cancer, locally widespread, combined operations, palliative gastrectomyAbstract
In the study, pancreatic involvement was observed in 91.2% of cases in T4 gastric cancer. Moreover, with the same frequency (34.5%), ingrowth into the pancreas was combined with damage to the transverse colon and around vessels. The prognostic factors that determine the survival of patients with T4 gastric cancer remain unclear. Data on the immediate results of combined operations performed for locally pervasive gastric cancer vary considerably in the literature. The frequency of postoperative complications ranges from 5 to 59.4%, postoperative mortality - from 3.3 to 24.2%. The optimal surgical tactics for the treatment of patients with locally widespread gastric cancer has not been determined. Not only the indications for combined resections and palliative interventions remain controversial, but also the immediate and long-term results of treatment, which determines the relevance of continuing research.
References
1. Aggarwal C. et al. A phase 1, open-label, dose-escalation study of enoblituzumab in combination with pembrolizumab in patients with select solid tumors // J. Immunother. Cancer. - 2018. - Т. 6. - №. Suppl. 2. - С. 114.
2. Aleksander S. A. et al. The Gene Ontology knowledgebase in 2023 // Genetics. -2023. - Т. 224. - №. 1. - С. iyad031.
3. Baj J. et al. Immunological aspects of the tumor microenvironment and epithelial-mesenchymal transition in gastric carcinogenesis // International journal of molecular sciences. - 2020. - Т. 21. - №. 7. - С. 2544.
4. Chen L. et al. Cancer associated fibroblasts promote renal cancer progression through a TDO/Kyn/AhR dependent signaling pathway // Frontiers in Oncology. -2021. - T. 11. - C. 628821.
5. Chen P., He Y., Zhou C. P47. 13 Galectin-9, A Novel Prognostic Factor in Small Cell Lung Cancer // Journal of Thoracic Oncology. - 2021. - T. 16. - №. 3. - C. S498.
6. Chocarro L. et al. Understanding LAG-3 signaling // International journal of molecular sciences. - 2021. - T. 22. - №. 10. - C. 5282.
7. Compagno D. et al. Galectins as checkpoints of the immune system in cancers, their clinical relevance, and implication in clinical trials // Biomolecules. - 2020. T. 10. - №. 5. - C. 750.
8. Cui J. et al. Pancancer analysis of revealed TDO2 as a biomarker of prognosis and immunotherapy //Disease Markers. - 2022. - T. 2022. - C. 1-18.
9. Doroshow D. B. et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors // Nature reviews Clinical oncology. - 2021. - T. 18. - №. 6. - C. 345362.
10. Edwards D. R., Handsley M. M., Pennington C. J. The ADAM metalloproteinases// Molecular aspects of medicine. - 2008. - T. 29. - №. 5. - C. 258-289.
11. Elad-Sfadia G. et al. Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity // Journal of Biological Chemistry. - 2004. - T. 279. - №. 33. - C. 34922-34930.
12. Gooz M. ADAM-17: the enzyme that does it all // Critical reviews in biochemistry and molecular biology. - 2010. - T. 45. - №. 2. - C. 146-169.
13. Gu L. et al. PD-L1 and gastric cancer prognosis: A systematic review and metaanalysis // PloS one. - 2017. - T. 12. - №. 8. - C. e0182692.
14. He W. et al. CD155T/TIGIT signaling regulates CD8+ T-cell metabolism and promotes tumor progression in human gastric cancer // Cancer research. - 2017. -T. 77. - №. 22. - C. 6375-6388.
15. Henson D. E. et al. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type // Archives of pathology & laboratory medicine. - 2004. - T. 128. - №. 7. - C. 765770.
16. Heusschen R., Griffioen A. W., Thijssen V. L. Galectin-9 in tumor biology: a jack of multiple trades // Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. -2013. - T. 1836. - №. 1. - C. 177-185.
17. Huang D. W. et al. CD155 expression and its correlation with clinicopathologic characteristics, angiogenesis, and prognosis in human cholangiocarcinoma // OncoTargets and therapy. - 2017. - C. 3817-3825.
18. Iguchi-Manaka A. et al. Increased soluble CD155 in the serum of cancer patients // PloS one. - 2016. - T. 11. - №. 4. - C. e0152982.
19. Joossens J. V. et al. Dietary salt, nitrate and stomach cancer mortality in 24 countries. European Cancer Prevention (ECP) and the INTERSALT Cooperative Research Group // International journal of epidemiology. - 1996. - T. 25. - №. 3. - c. 494-504.
20. Keir M. E. et al. PD-1 and its ligands in tolerance and immunity // Annu. Rev. Immunol. - 2008. - T. 26. - № 1. - C. 677-704.
21. Kim S. J. et al. Fascin expression is related to poor survival in gastric cancer // Pathology international. - 2012. - T. 62. - №. 12. - C. 777-784.
22. Larsson S. C., Bergkvist L., Wolk A. Fruit and vegetable consumption and incidence of gastric cancer: a prospective study // Cancer Epidemiology Biomarkers & Prevention. - 2006. - T. 15. - №. 10. - C. 1998-2001.
23. Lee B. H. et al. Prognostic value of galectin-9 relates to programmed death-ligand 1 in patients with multiple myeloma // Frontiers in Oncology. - 2021. - T. 11. - C. 669817.
24. Li F. et al. CD4/CD8+ T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis // Cancer medicine. - 2019a. - T. 8. - №. 17. - C. 7330-7344.
25. Li Y. C. et al. Overexpression of an immune checkpoint (CD155) in breast cancer associated with prognostic significance and exhausted tumor-infiltrating lymphocytes: a cohort study // Journal of immunology research. - 2020. - T. 2020. - C. 1-9.
26. Li Y. et al. B7-H3 increases the radioresistance of gastric cancer cells through regulating baseline levels of cell autophagy // American journal of translational research. - 2019c. - Т. 11. - №. 7. - С. 4438-4449.
27. Linsley P. S. et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors // Immunity. - 1994. Т. 1. - №. 9. - С. 793-801.
28. Liu H. et al. Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma // Scientific Reports. -2016. - Т. 6. - №. 1. - С. 21319.
29. Lordick F. et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up^ // Annals of Oncology. - 2022. - Т. 33. - №. 10. - С. 1005-1020.
30. Lu S. et al. Expression of indoleamine 2, 3-dioxygenase 1 (IDO1) and tryptophanyl-tRNA synthetase (WARS) in gastric cancer molecular subtypes // Applied immunohistochemistry & molecular morphology: AIMM. - 2020. - T. 28. - №. 5. - C. 360-368.
31. Ma W. et al. Targeting immunotherapy for bladder cancer by using anti-CD3x CD155 bispecific antibody //Journal of Cancer. - 2019. - T. 10. - №. 21. - C. 5153-5161.
32. Mai P. L. et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort // Cancer. - 2016. -T. 122. - №. 23. - C. 3673-3681.
33. Masciari S. et al. Gastric cancer in individuals with Li-Fraumeni syndrome // Genetics in Medicine. - 2011. - T. 13. - №. 7. - C. 651-657.
34. McDermott D. et al. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20) // Annals of Oncology. - 2013. - T. 24. - №. 10. - C. 2694-2698.
35. Möller-Hackbarth K. et al. A disintegrin and metalloprotease (ADAM) 10 and ADAM17 are major sheddases of T cell immunoglobulin and mucin domain 3 (Tim-3) // Journal of Biological Chemistry. - 2013. - T. 288. - №2. 48. - C. 3452934544.
36. Moss M. L. et al. Recent advances in ADAM17 research: a promising target for cancer and inflammation // Mediators of inflammation. - 2017. - T. 2017. C. 121.
37. Nakahara S., Raz A. Regulation of cancer-related gene expression by galectin-3 and the molecular mechanism of its nuclear import pathway // Cancer and Metastasis Reviews. - 2007. - T. 26. - № 3-4. - C. 605-610.
38. Ochs K. et al. Tryptophan-2, 3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4 // Journal of neurochemistry. - 2016. - T. 136. - №. 6. - C. 1142-1154.
39. Okada K. et al. Reduced galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer // Anticancer research. - 2006. - T. 26. - №. 2B. - C. 1369-1376.
40. Parsonnet J. et al. Helicobacter pylori infection in intestinal-and diffuse-type gastric adenocarcinomas // JNCI: Journal of the National Cancer Institute. - 1991. T. 83. - №. 9. - C. 640-643.
41. Patel S. P., Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy // Molecular cancer therapeutics. - 2015. - T. 14. - №2. 4. - C. 847856.
42. Peyraud F. et al. Targeting tryptophan catabolism in cancer immunotherapy era: challenges and perspectives // Frontiers in Immunology. - 2022. - T. 13. - C. 807271.
43. Kuliev A.A., Juraev M.D. и др. // Turkish Journal of Physiotherapy and Rehabilitation; 32(3) 2021. C 7242-7245
44. Кулиев А.А., Джураев М.Д. и др. // Academic research in educational sciences scientific journal 2021. №2. C 291-307
45. Кулиев А.А., Джураев М.Д. и др. // Журнал биомедицины и практики; №2 2021. C 132-138.
46. Kuliev A.A., Juraev M.D. и др. // The American Journal of Medical Sciences and Pharmaceutical Research (ISSN – 2689-1026) 2023. C 70-77.
